3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review

Yibeltal Assefa; Yalemzewod Assefa; Solomon Woldeyohannes; Yohhei Hamada; Haileyesus Getahun

doi:10.1183/13993003.00395-2018

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review

Eur Respir J. 2018 Jul 11;52(1):1800395. doi: 10.1183/13993003.00395-2018. Print 2018 Jul.

Authors

Yibeltal Assefa¹, Yalemzewod Assefa¹, Solomon Woldeyohannes¹, Yohhei Hamada², Haileyesus Getahun²

Affiliations

¹ School of Public Health, the University of Queensland, Brisbane, Australia.
² Global TB Programme, World Health Organization, Geneva, Switzerland.

Abstract

Treatment of latent tuberculosis infection in children with a 3-month daily rifampicin and isoniazid regimen is safe with better compliance, adherence and completion rate than a 6- or 9-month isoniazid monotherapy http://ow.ly/x28Z30jDfCE

Publication types

Letter
Systematic Review

MeSH terms

Adolescent
Antitubercular Agents / administration & dosage*
Antitubercular Agents / adverse effects
Child
Drug Administration Schedule
Drug Therapy, Combination
Humans
Isoniazid / administration & dosage*
Isoniazid / adverse effects
Latent Tuberculosis / drug therapy*
Rifampin / administration & dosage*
Rifampin / adverse effects

Substances

Antitubercular Agents
Isoniazid
Rifampin

Grants and funding

001/WHO_/World Health Organization/International